EUVIMEDEUVIMED entdecken
Crossref

Ellagic acid from Terminalia leiocarpa downregulates estrogen-dependent signaling and epithelial-to-mesenchymal transition canonical pathways in MCF-7 cells

Temitope O. Lawal, Pinal N. Kanabar, Nina S. Los, Shitalben M. Patel, Mark Maienschein-Cline, Zarema H. Arbieva, Bolanle A. Adeniyi, Gail B. Mahady

Innovative Medicines & Omics · 07.04.2026 · 3 (2) · 025470062

DOI: 10.36922/imo025470062 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Innovative Medicines & Omics, online erschienen am 07.04.2026. Verfasst von Temitope O. Lawal und 7 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Breast cancer remains the most diagnosed cancer among women worldwide, and its prevalence continues to increase annually. Previously, we reported that ellagic acid (EA), a compound isolated from Terminalia leiocarpa (DC.) Baill., a plant used in Nigerian traditional medicine, inhibited the proliferation of cultured human MCF-7 breast cancer cells. EA is a pharmacologically active polyphenolic compound with antioxidant, anti-inflammatory, and anti-estrogenic activities. In this work, we investigated the effects of EA on the transcriptome of MCF-7 cells using next-generation sequencing. After EA treatment, MCF-7 cells were harvested, and total RNA was isolated and used to prepare RNA sequencing libraries. Sequencing was performed using NovaSeq 6000. The results showed that EA significantly altered gene expression patterns in MCF-7 cells. Bioinformatic analysis of the sequencing data revealed that 4,848 transcripts were differentially expressed, with 2,180 upregulated genes and 2,668 downregulated genes (q ≤ 0.01). Ingenuity Pathway Analysis indicated that EA-induced expression changes mapped to 98 canonical pathways, including upregulation of apoptosis signaling pathways and downregulation of estrogen signaling and estrogen-dependent breast cancer signaling pathways (q ≤ 0.05). Furthermore, EA downregulated gene expression in the epithelial-to-mesenchymal transition (EMT) canonical pathway, such as PRRX1/2, TGF, TWIST1, and VIM. These data indicate that EA has multiple mechanisms of action in MCF-7 cells, including the induction of apoptosis and the reduction of both estrogen and EMT signaling. Thus, with further research, EA may serve as an inexpensive, safe, and effective treatment for breast cancer and metastatic diseases.

Zitieren

APA

Lawal, T. O., Kanabar, P. N., Los, N. S., Patel, S. M., Maienschein-Cline, M., Arbieva, Z. H., Adeniyi, B. A., & Mahady, G. B. (2026). Ellagic acid from Terminalia leiocarpa downregulates estrogen-dependent signaling and epithelial-to-mesenchymal transition canonical pathways in MCF-7 cells. Innovative Medicines & Omics, 3(2), 025470062. https://doi.org/10.36922/imo025470062

Vancouver

Lawal TO, Kanabar PN, Los NS, Patel SM, Maienschein-Cline M, Arbieva ZH, et al. Ellagic acid from Terminalia leiocarpa downregulates estrogen-dependent signaling and epithelial-to-mesenchymal transition canonical pathways in MCF-7 cells. Innovative Medicines & Omics. 2026;3(2):025470062. doi:10.36922/imo025470062

BibTeX
@article{Lawal2026,
  author = {Lawal, Temitope O. and Kanabar, Pinal N. and Los, Nina S. and Patel, Shitalben M. and Maienschein-Cline, Mark and Arbieva, Zarema H. and Adeniyi, Bolanle A. and Mahady, Gail B.},
  title = {Ellagic acid from Terminalia leiocarpa downregulates estrogen-dependent signaling and epithelial-to-mesenchymal transition canonical pathways in MCF-7 cells},
  journal = {Innovative Medicines & Omics},
  year = {2026},
  volume = {3},
  number = {2},
  pages = {025470062},
  doi = {10.36922/imo025470062}
}
Kostenlos starten →